<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01377077</url>
  </required_header>
  <id_info>
    <org_study_id>SNIP punchgrafting study</org_study_id>
    <nct_id>NCT01377077</nct_id>
  </id_info>
  <brief_title>Punchgrafting Techniques for Vitiligo</brief_title>
  <acronym>MiniSNIP</acronym>
  <official_title>Autologous Punch Grafting in Vitiligo Patients: the Effect of Punchdepth and Punchsize</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Punch grafting is a safe, simple and widely used technique for in vitiligo.&#xD;
      However, no reliable data are available on the effect of punch depth and punch size.&#xD;
&#xD;
      Objectives: Primary: to compare the efficacy and safety of different punchdepths and&#xD;
      punchsizes in punch grafting in patients with segmental and non-segmental vitiligo.&#xD;
      Secondary: to assess the practical aspects and patients preference of different punch&#xD;
      grafting techniques.&#xD;
&#xD;
      Study design: Prospective observer blinded randomised controlled study. Study population: 35&#xD;
      patients â‰¥ 18 years with segmental or stable non-segmental vitiligo who will receive regular&#xD;
      treatment by punch grafting at the Netherlands Institute for Pigment Disorders (SNIP) at the&#xD;
      Academic Medical Centre University of Amsterdam.&#xD;
&#xD;
      Methods: Four depigmented regions on the trunk or upper extremities will be randomly&#xD;
      allocated to either epidermal 1,5 mm punch grafting, epidermal 1mm punch grafting, dermal 1,5&#xD;
      mm punch grafting and dermal 1 mm punch grafting. After grafting, all regions will receive&#xD;
      UV-therapy twice a week for 3 months. Three and six months after grafting, the repigmentation&#xD;
      of the lesions will be assessed by measuring the outgrowth.&#xD;
&#xD;
      Main study parameter/endpoint: Outgrowth of pigment after six months.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: The study involves 16 additional punch grafts but no additional visits to our&#xD;
      institute. Patients will not miss any regular treatment. The extra time due to participation&#xD;
      in the study will be about 40 minutes. No increase of the risk of side effects is expected by&#xD;
      placing 16 additional punch grafts. 1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outgrowth of pigment after six months</measure>
    <time_frame>at 3 and 6 months after treatment</time_frame>
    <description>Objective assessment of the repigmentation 3 and 6 months after punch grafting. Assessment will be done using a ruler on a dermatoscope to measure the diameter of the growth of the punchgrafts. The surface of repigmentation will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual assessment of side effects</measure>
    <time_frame>at 3 and 6 months after treatment</time_frame>
    <description>Visual assessment of side effects (hyperpigmentation, hypopigmentation, scar, cobble stone effect on a scale from 0-3) by a blinded investigator.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Non-segmental Vitiligo</condition>
  <condition>Segmental Vitiligo</condition>
  <condition>Piebaldism</condition>
  <arm_group>
    <arm_group_label>epidermal 1mm grafting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epidermal skin biopsies of 1mm diameter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dermal 1mm grafting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dermal skinbiopsies of 1mm diameter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dermal 1,5mm grafting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dermal skinbiopsies of 1,5mm diameter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>epidermal 1,5mm grafting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>epidermal skinbiopsies of 1,5mm diameter</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>punchgrafting</intervention_name>
    <description>autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions</description>
    <arm_group_label>dermal 1mm grafting</arm_group_label>
    <arm_group_label>epidermal 1,5mm grafting</arm_group_label>
    <arm_group_label>epidermal 1mm grafting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>punchgrafting</intervention_name>
    <description>autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions</description>
    <arm_group_label>dermal 1,5mm grafting</arm_group_label>
    <arm_group_label>dermal 1mm grafting</arm_group_label>
    <arm_group_label>epidermal 1,5mm grafting</arm_group_label>
    <arm_group_label>epidermal 1mm grafting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with non-segmental and segmental vitiligo under medical treatment at the&#xD;
             Netherlands Institute for Pigment Disorders&#xD;
&#xD;
          -  Age between 18 and 60 years&#xD;
&#xD;
          -  Patient is willing and able to give written informed consent&#xD;
&#xD;
          -  Vitiligo stable since 12 months without systemic therapy or 6 months without topical&#xD;
             therapy as defined by the absence of new lesions and/or enlargement of existing&#xD;
             lesions.&#xD;
&#xD;
          -  Vitiligo lesions on the extremities or trunk larger than 5x5cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  UV therapy or systemic immunosuppressive treatment during the last 12 months&#xD;
&#xD;
          -  Local treatment of vitiligo during the last 6 months&#xD;
&#xD;
          -  Vitiligo lesions with folliculair or non-folliculair repigmentations&#xD;
&#xD;
          -  Skin type 1&#xD;
&#xD;
          -  Hypertrophic scars&#xD;
&#xD;
          -  Keloid&#xD;
&#xD;
          -  Cardial insufficiency&#xD;
&#xD;
          -  Patients with a history of hypersensitivity to (UVB) light and allergy to local&#xD;
             anesthesia.&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding&#xD;
&#xD;
          -  Patients not competent to understand what the procedures involved&#xD;
&#xD;
          -  Patients with a personal history of melanoma or non-melanoma skin cancer&#xD;
&#xD;
          -  Patients with a first degree relative with melanoma skin cancer&#xD;
&#xD;
          -  Patients with atypical nevi.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Netherlands Institute for Pigmentdisorders</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Vrijman, MD</last_name>
      <phone>0031205662575</phone>
      <email>c.vrijman@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Charlotte Vrijman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>June 17, 2011</study_first_submitted>
  <study_first_submitted_qc>June 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2011</study_first_posted>
  <last_update_submitted>June 20, 2011</last_update_submitted>
  <last_update_submitted_qc>June 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Albert Wolkerstorfer, MD PhD</name_title>
    <organization>Netherlands Institute for Pigmentdisorders</organization>
  </responsible_party>
  <keyword>vitiligo</keyword>
  <keyword>piebaldism</keyword>
  <keyword>punchgrafting</keyword>
  <keyword>minigrafting</keyword>
  <keyword>stable for at least 12 months</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piebaldism</mesh_term>
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

